Trial Profile
An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs AVR RD 01 (Primary) ; Busulfan
- Indications Fabry's disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors AVROBIO
- 04 Jan 2022 According to an AVROBIO media release, the company will stop enrollment for this clinical trial and continue monitoring the previously dosed patients for a total of 15 years as required by regulators.
- 04 Jan 2022 Status changed from recruiting to discontinued, according to an AVROBIO media release.
- 24 Nov 2021 Results presented in an AVROBIO Media Release.